Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," ...

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over radiotherapy alone.1 Mechanisms proposed to explain this effect include ...

Men with prostate cancer are being denied NHS access to a treatment used by Lord Cameron, a senior doctor has revealed.

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...

Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...

The average age of men who get diagnosed is 67.

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, ...

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Award, which will ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...